EDIT
HealthcareEditas Medicine, Inc.
$1.99
$-0.06 (-2.93%)
Jan 5, 2026
Price History (1Y)
Analysis
Editas Medicine, Inc. is a biotechnology company within the healthcare sector, with a market capitalization of $194.26M and approximately 246 employees. The company's industry is characterized by significant research and development in genetic engineering. Financially, Editas Medicine has reported a net income loss of $199,835,008 over the trailing twelve months (TTM), with an EBITDA of -$112,038,000 and free cash flow of -$65,967,500. The company's gross margin is -139.7%, operating margin is -325.4%, and profit margin is 0.0%. Additionally, Editas Medicine has a return on equity (ROE) of -211.4% and a return on assets (ROA) of -28.3%. The company's balance sheet shows $165.65M in cash and $19.65M in debt. Editas Medicine's valuation metrics include a forward P/E ratio of -1.87, price to book ratio of 13.82, and price to sales ratio of 4.19. The company has a revenue growth rate of 12265.6% year-over-year (YoY), although the earnings growth rate is not available.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $194.26M
- P/E Ratio
- N/A
- 52-Week High
- $4.54
- 52-Week Low
- $0.91
- Avg Volume
- 2.18M
- Beta
- 2.16
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 246